GDM & LGA Infants: Oral Agent Reply
- Su regarding a recent article, the study's authors addressed the selection of an 8% noninferiority margin for the primary outcome.
- The researchers maintain that a smaller margin woudl not have altered their main finding of noninferiority.
- Specifically,a larger sample size might have allowed them to detect smaller differences in clinically relevant secondary outcomes.
Study authors respond decisively to critical feedback, defending their noninferiority margin choices. Researchers clarify their methods, emphasizing that the 8% margin aligns with established research, expert consensus. They acknowledge that while a larger sample size in studies on GDM & LGA infants might have unveiled subtle differences in secondary outcomes, their main finding of noninferiority remains valid. The authors maintain their conclusions and address concerns. They conceded a larger participant group might have yielded different results for the secondary outcomes.News Directory 3 is yoru source for this breaking information.Further studies will explore these potential refinements for future clinical guidelines. Discover what’s next….
Study Authors Address Sample Size, Margin Concerns in Research Reply
Updated June 19, 2025
In response to concerns raised by Dr. Su regarding a recent article, the study’s authors addressed the selection of an 8% noninferiority margin for the primary outcome. They stated this margin was based on both prior research in the field and expert consensus,which deemed it a clinically acceptable difference.
The researchers maintain that a smaller margin woudl not have altered their main finding of noninferiority. However,they conceded that a larger sample size could have been beneficial.
Specifically,a larger sample size might have allowed them to detect smaller differences in clinically relevant secondary outcomes. These outcomes included neonatal hypoglycemia and adverse effects experienced by mothers.
What’s next
Future research may focus on studies with larger participant groups to explore subtle differences in secondary outcomes, potentially refining clinical guidelines.